Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
EVFM Evofem Biosciences, Inc. daily Stock Chart
EVFM [NASD]
Evofem Biosciences, Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)-1.91 Insider Own2.80% Shs Outstand48.20M Perf Week-19.52%
Market Cap297.59M Forward P/E- EPS next Y-1.13 Insider Trans-3.54% Shs Float61.43M Perf Month-6.80%
Income-81.10M PEG- EPS next Q-0.35 Inst Own59.30% Short Float4.19% Perf Quarter-22.46%
Sales- P/S- EPS this Y65.40% Inst Trans23.18% Short Ratio3.21 Perf Half Y-23.73%
Book/sh0.02 P/B233.00 EPS next Y2.00% ROA-236.20% Target Price- Perf Year-21.81%
Cash/sh0.16 P/C28.61 EPS next 5Y73.50% ROE-424.00% 52W Range3.34 - 7.50 Perf YTD-24.47%
Dividend- P/FCF- EPS past 5Y42.70% ROI- 52W High-53.53% Beta0.34
Dividend %- Quick Ratio0.90 Sales past 5Y- Gross Margin- 52W Low4.34% ATR0.51
Employees53 Current Ratio0.90 Sales Q/Q- Oper. Margin- RSI (14)29.73 Volatility9.98% 9.59%
OptionableYes Debt/Eq0.00 EPS Q/Q40.90% Profit Margin- Rel Volume38.94 Prev Close4.66
ShortableYes LT Debt/Eq0.00 EarningsMay 06 BMO Payout- Avg Volume801.44K Price3.48
Recom1.70 SMA20-32.31% SMA50-31.67% SMA200-35.16% Volume14,711,930 Change-25.21%
Oct-16-19Resumed Cantor Fitzgerald Overweight $9
Jun-02-20 11:03PM  
Evofem Announces Pricing of Approximately $100 Million Public Offering of Common Stock
PR Newswire -7.91%
04:01PM  
Evofem Announces Proposed Public Offering of Common Stock
PR Newswire
May-31-20 05:15PM  
Is Evofem Biosciences, Inc. (EVFM) A Good Buy According To Hedge Funds?
Insider Monkey
May-28-20 06:30AM  
Finally, Some Good News for Evofem Biosciences
Motley Fool -6.75%
May-27-20 10:56AM  
Company News for May 27, 2020
Zacks
08:55AM  
Are Options Traders Betting on a Big Move in Evofem Biosciences (EVFM) Stock?
Zacks
May-26-20 10:32AM  
A Look Into Evofem Biosciences' Price Over Earnings
Benzinga +16.03%
09:52AM  
Evofem Biosciences Soars as Birth-Control Gel Receives FDA OK
TheStreet.com
09:00AM  
Why Evofem Biosciences Stock Is on Fire Today
Motley Fool
08:42AM  
Evofem Biosciences Rallies on Contraceptive Gel Approval: What's Next?
TheStreet.com
May-22-20 04:37PM  
Evofem stock rallies as FDA approves birth-control gel
MarketWatch
04:05PM  
U.S. FDA Approves Evofem Biosciences' Phexxi (lactic acid, citric acid and potassium bitartrate), the First and Only Non-Hormonal Prescription Gel for the Prevention of Pregnancy
PR Newswire
01:09PM  
Birth Control Gel Approved as First No-Hormone Option in Decades
Bloomberg
01:07PM  
Evofem's gel first non-hormonal contraceptive to get approval in over 30 years
Reuters
01:07PM  
Evofem non-hormonal birth control gel gets FDA approval, to be priced at up to $275
Reuters
May-21-20 04:05PM  
PDL BioPharma Completes Distribution of Evofem Biosciences Common Stock to PDL Stockholders
PR Newswire
May-18-20 04:05PM  
PDL BioPharma Declares Distribution Ratio for Dividend of Evofem Biosciences Common Stock to PDL Stockholders
PR Newswire
May-13-20 08:00AM  
Evofem Biosciences to Participate in Virtual Fireside Chat at RBC Capital Markets Global Healthcare Conference
PR Newswire
May-08-20 09:00AM  
PDL Biopharma Inc (PDLI) Q1 2020 Earnings Call Transcript
Motley Fool
May-07-20 07:30AM  
Evofem Biosciences, Inc. (EVFM) Q1 2020 Earnings Call Transcript
Motley Fool
May-06-20 10:44PM  
Edited Transcript of EVFM earnings conference call or presentation 6-May-20 3:00pm GMT
Thomson Reuters StreetEvents
08:00AM  
Evofem Biosciences Reports First Quarter 2020 Financial Results and Provides Corporate Update
PR Newswire
May-01-20 05:21PM  
Evofem Biosciences Announces New Location and COVID-19 Preventative Measures for 2020 Annual Meeting Scheduled for May 12, 2020
PR Newswire +5.49%
Apr-28-20 08:00AM  
Evofem Biosciences to Report First Quarter 2020 Results and Provide Corporate Update on Wednesday, May 6, 2020
PR Newswire -7.50%
Apr-24-20 08:30AM  
Evofem Biosciences Announces Three New Phexxi Data Sets Accepted for Presentation at the 2020 American College of Obstetricians and Gynecologists (ACOG) Annual Meeting
PR Newswire
Apr-19-20 07:02AM  
3 Top Biotech Stocks with FDA Approvals on the Horizon
TipRanks
Apr-10-20 04:05PM  
Evofem Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire
Mar-30-20 05:14PM  
Edited Transcript of EVFM earnings conference call or presentation 12-Mar-20 3:00pm GMT
Thomson Reuters StreetEvents +7.96%
Mar-27-20 08:30AM  
Evofem Biosciences to Present at Solebury Trout Virtual Investor Conference
PR Newswire
Mar-25-20 05:00PM  
Evofem Biosciences Adopts Shareholder Rights Agreement
PR Newswire
Mar-24-20 04:00PM  
Solebury Trout Announces Virtual Conference Series with Presentations from Life Science Companies
ACCESSWIRE +11.05%
Mar-19-20 08:15AM  
TRACON Pharmaceuticals Announces Appointment of Saundra Pelletier to Board of Directors
GlobeNewswire +11.90%
Mar-12-20 09:00AM  
Evofem Biosciences, Inc. to Host Earnings Call
ACCESSWIRE -23.06%
08:00AM  
Evofem Biosciences Reports Fourth Quarter and Year-end 2019 Financial Results and Provides Corporate Update
PR Newswire
Mar-09-20 11:53AM  
We're Keeping An Eye On Evofem Biosciences's (NASDAQ:EVFM) Cash Burn Rate
Simply Wall St. -12.48%
Feb-26-20 08:30AM  
Evofem Biosciences Appoints Former FDA Division Director Lisa Rarick, M.D., to its Board of Directors
PR Newswire
Feb-16-20 08:25AM  
3 Monster Growth Stocks That Can Charge Forward in 2020
TipRanks
Dec-22-19 05:32PM  
Hedge Funds Have Never Been This Bullish On Evofem Biosciences, Inc. (EVFM)
Insider Monkey
Dec-18-19 07:30AM  
U.S. FDA Acknowledges Receipt of Evofem Biosciences' New Drug Application Resubmission for Amphora® for the Prevention of Pregnancy
PR Newswire
Dec-03-19 09:00AM  
PDL BioPharma Congratulates Evofem Biosciences on Achieving Major Regulatory and Clinical Milestones with its Lead Product Candidate Amphora®
PR Newswire
07:59AM  
The Daily Biotech Pulse: Astellas To Buy Audentes For $3B, Applied Genetics Chief Medical Officer Quits, Axsome Aces Midstage Trial
Benzinga
Dec-02-19 08:07AM  
Benzinga Pro's Top 5 Stocks To Watch For Mon., Dec. 2, 2019: EVFM, AQMS, ROKU, TDOC, COUP
Benzinga +12.27%
07:18AM  
UPDATE: Evofem Biosciences stock soars 27% premarket on news of positive results in trial of drugs for STDs
MarketWatch
06:50AM  
Evofem Biosciences Reports Positive Top-Line Results from Phase 2b Study of Amphora® for Prevention of Chlamydia and Gonorrhea in Women
PR Newswire
Nov-24-19 04:19PM  
The Week Ahead In Biotech: Aquestive Awaits FDA Decision, Arrowhead Earnings And More
Benzinga
Nov-19-19 03:32PM  
Edited Transcript of EVFM earnings conference call or presentation 7-Nov-19 4:00pm GMT
Thomson Reuters StreetEvents
Nov-14-19 08:00AM  
Evofem Biosciences' CEO Saundra Pelletier Awarded 2019 Business Woman Of The Year
PR Newswire
Nov-13-19 04:05PM  
Evofem Biosciences to Participate in Upcoming Investor Conferences
PR Newswire
Nov-08-19 08:30PM  
Avid Technology, Callon Petroleum, Orion Group, and Other 13D Filings
Barrons.com
Nov-07-19 11:26AM  
PDL BioPharma (PDLI) Q3 Earnings Beat, LENSAR Drives Sales
Zacks
Nov-06-19 04:05PM  
Evofem Biosciences Reports Third Quarter 2019 Financial Results and Provides Corporate Update
PR Newswire
Oct-24-19 09:00AM  
Evofem Biosciences to Report Third Quarter 2019 Results and Provide Corporate Update on November 7, 2019
PR Newswire
Sep-25-19 09:00AM  
Evofem Biosciences to Present at Cantor Global Healthcare Conference on October 4, 2019
PR Newswire
Sep-11-19 01:31PM  
What Type Of Shareholder Owns Evofem Biosciences, Inc.'s (NASDAQ:EVFM)?
Simply Wall St.
Aug-26-19 06:00AM  
Evofem Biosciences Completes Phase 2b 'AMPREVENCE' Trial of Amphora for Prevention of Chlamydia and Gonorrhea in Women
PR Newswire
Aug-22-19 09:30AM  
Evofem Biosciences to Present at Upcoming Healthcare Conferences
PR Newswire
Aug-08-19 11:23AM  
PDL Biopharma Inc (PDLI) Q2 2019 Earnings Call Transcript
Motley Fool +6.20%
10:17AM  
PDL BioPharma (PDLI) Q2 Earnings Top Mark, Revenues Fall Y/Y
Zacks
Aug-07-19 08:24PM  
Edited Transcript of EVFM earnings conference call or presentation 6-Aug-19 3:00pm GMT
Thomson Reuters StreetEvents -6.38%
Aug-05-19 04:10PM  
Evofem Biosciences Reports Second Quarter 2019 Financial Results and Provides Corporate Update
PR Newswire
04:05PM  
Evofem Biosciences Reports Additional Data from Phase 3 'AMPOWER' Study of Amphora® for Hormone-Free Birth Control
PR Newswire
Jul-30-19 09:00AM  
Evofem Biosciences to Report Second Quarter 2019 Results and Provide Corporate Update on August 6, 2019
PR Newswire
Jul-01-19 09:31AM  
Evofem Biosciences Added to Russell 3000® Index
PR Newswire -14.91%
Jun-10-19 04:01PM  
Evofem Biosciences Closes $80 Million Financing Transaction with PDL BioPharma and Other Long-time Investors
PR Newswire
May-30-19 11:02AM  
PDL BioPharma's Royalties Help, Heavy Partner Reliance Hurts
Zacks +8.78%
May-14-19 09:00AM  
Evofem Biosciences to Present at 2019 RBC Capital Markets Global Healthcare Conference
PR Newswire +6.80%
May-10-19 10:51AM  
PDL BioPharma (PDLI) Q1 Earnings Top Mark, Revenues Rise Y/Y
Zacks +16.87%
May-09-19 07:24PM  
PDL Biopharma Inc (PDLI) Q1 2019 Earnings Call Transcript
Motley Fool
May-07-19 06:00AM  
Evofem Biosciences Reports First Quarter 2019 Financial Results and Provides Corporate Update
PR Newswire +5.70%
Apr-30-19 09:00AM  
Evofem Biosciences to Report First Quarter 2019 Results and Provide Corporate Update on May 7, 2019
PR Newswire
Apr-23-19 08:11AM  
Evofem Biosciences Announces Last Patient Enrolled for AMPREVENCE, the Phase 2b Sexually Transmitted Infections Trial of Amphora
PR Newswire -6.62%
Apr-16-19 08:30AM  
STOCKHOLDER ALERT: Kaskela Law LLC Announces Investigation of Evofem Biosciences, Inc. EVFM
GlobeNewswire
Apr-11-19 10:25AM  
PDL BioPharma Announces Equity Investment in Evofem Biosciences
PR Newswire +14.88%
10:19AM  
Evofem Biosciences Enters into Financing Agreement for up to $80 Million, Closes First Tranche of Strategic Investment from PDL BioPharma
PR Newswire
06:54AM  
Evofem Biosciences raises $80m for new hormone-free contraceptive
Financial Times
Apr-03-19 09:00AM  
Evofem Biosciences to Present at Needham Healthcare Conference
PR Newswire
Mar-12-19 09:00AM  
Evofem Biosciences to Present at Upcoming Investor Conferences
PR Newswire
Mar-03-19 11:00PM  
Edited Transcript of EVFM earnings conference call or presentation 1-Mar-19 4:00pm GMT
Thomson Reuters StreetEvents
Mar-01-19 06:00AM  
Evofem Biosciences Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update
PR Newswire -12.05%
Feb-19-19 09:00AM  
Evofem Biosciences to Report Fourth Quarter and Year-end 2018 Results and Provide Corporate Update on March 1, 2019
PR Newswire
Jan-07-19 07:20AM  
Evofem Biosciences, Amphora a Potential New Birth Control, Analysts Review and Target
ACCESSWIRE
Jan-03-19 08:00AM  
Evofem Biosciences Provides Corporate Update and Announces Upcoming Milestones
PR Newswire -5.66%
07:06AM  
Edited Transcript of EVFM earnings conference call or presentation 7-Nov-18 4:00pm GMT
Thomson Reuters StreetEvents
Dec-20-18 10:13AM  
The Zacks Analyst Blog Highlights: Amgen, Aduro, Vertex, Evofem and Incyte
Zacks
Dec-19-18 09:17AM  
Biotech Stock Roundup: Pipeline Updates From VRTX & AMGN, ADRO Teams Up With LLY
Zacks
Dec-18-18 02:01PM  
Evofem Shares Up as Birth Control Gel Succeeds in Phase III
Zacks -15.80%
06:55AM  
Today's Research Reports on Trending Tickers: Evofem Biosciences and Diffusion Pharmaceuticals
ACCESSWIRE
Dec-17-18 01:30PM  
4 Stocks Providing Investor Opportunity Right Now
ACCESSWIRE +14.42%
06:22AM  
Evofem's hormone-free birth control gel meets main goal in key study
Reuters
06:00AM  
Evofem Biosciences Announces Positive Top-Line Results of Phase 3 Study Evaluating Amphora for Hormone-Free Birth Control
PR Newswire
Nov-15-18 06:50AM  
Evofem Biosciences to Present at Piper Jaffray Healthcare Conference on November 27, 2018
PR Newswire
Nov-08-18 06:50AM  
Evofem Biosciences Completes Phase 3 Clinical Trial of Amphora for Prevention of Pregnancy
PR Newswire
Nov-07-18 06:50AM  
Evofem Biosciences Reports Third Quarter 2018 Financial Results and Provides Corporate Update
PR Newswire -8.25%
Nov-01-18 08:00AM  
Evofem Biosciences to Host Key Opinion Leader Event: New Perspectives in Birth Control--Non-Hormonal, On Demand and Woman Controlled
PR Newswire +7.16%
Oct-24-18 08:30AM  
Evofem Biosciences to Report Third Quarter 2018 Results on November 7, 2018
PR Newswire -7.14%
Oct-09-18 02:21PM  
Data on Patient Acceptability and Genitourinary Effects of Evofem Biosciences' Lead Product Candidate, Amphora, and its Role as a Multipurpose Vaginal pH Regulator Presented at 2018 American Society of Reproductive Medicine Annual Congress
PR Newswire
Sep-26-18 08:00AM  
Survey Reveals High Number of Sexually Active Women Who Use No Birth Control Method, Supporting the Continued Need for Non-Hormonal Birth Control Innovations such as Evofem Biosciences' Product Candidate Amphora®
PR Newswire +9.88%
Sep-21-18 08:00AM  
New Data on Patient Acceptability and Genitourinary Effects of Evofem Biosciences' Amphora and its Role as a Multipurpose Vaginal pH Regulator (MVP-R) to be Presented at the 2018 American Society For Reproductive Medicine (ASRM) Annual Congress
PR Newswire
Sep-18-18 08:00AM  
Evofem Biosciences to Present at Upcoming Investor Conferences
PR Newswire
Sep-11-18 10:24AM  
3 Small Biotech Stocks That Almost Doubled in Past Month
Zacks -14.50%
Evofem Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes women's sexual and reproductive health products. Its lead product candidate is Amphora, a non-hormonal woman-controlled vaginal gel, which is in Phase 3 clinical trial for the prevention of pregnancy; and in Phase 2b trial for the prevention of chlamydia and gonorrhea in women. The company is also developing multi-purpose vaginal pH regulator gel product candidate for the reduction of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Culwell KellyChief Medical OfficerMay 01Sale4.751,0004,750194,226May 01 08:12 PM
Culwell KellyChief Medical OfficerApr 30Sale4.661,0004,660195,226May 01 08:12 PM
Lynch Thomas GDirectorMar 31Option Exercise0.0037,5000325,000Apr 01 04:11 PM
Barrans RussellChief Commercial OfficerFeb 19Sale6.5014,95797,221332,240Feb 21 02:10 PM
Culwell KellyChief Medical OfficerFeb 19Sale7.001,0007,000196,226Feb 21 02:10 PM
Barrans RussellChief Commercial OfficerJan 16Sale6.501,57810,257196,298Jan 21 01:13 PM
PELLETIER SAUNDRA LChief Executive OfficerJan 13Sale6.003,29519,770362,289Jan 15 04:22 PM
File Justin J.Chief Financial OfficerJan 13Sale6.001,6489,888177,251Jan 15 04:22 PM
File Justin J.Chief Financial OfficerJan 02Sale6.053,35220,280178,899Jan 06 03:07 PM
PELLETIER SAUNDRA LChief Executive OfficerJan 02Sale6.056,70540,565365,584Jan 06 03:08 PM
Lynch Thomas GDirectorDec 31Option Exercise0.0037,5000287,500Dec 31 08:48 PM
Culwell KellyChief Medical OfficerDec 02Sale7.351,0007,35043,538Dec 04 05:34 PM
PELLETIER SAUNDRA LChief Executive OfficerDec 02Sale7.3020,000146,000372,289Dec 04 05:33 PM
File Justin J.Chief Financial OfficerDec 02Sale7.1610,00071,600182,251Dec 04 05:33 PM
File Justin J.Chief Financial OfficerNov 21Sale6.004,90029,400202,353Nov 21 08:18 PM
PELLETIER SAUNDRA LChief Executive OfficerNov 21Sale6.0110,00060,100414,676Nov 21 08:18 PM
File Justin J.Chief Financial OfficerNov 20Sale6.00100600207,253Nov 21 08:18 PM
open in yahoo | open in reuters | open in google